| Title | Author(s) | Issue date | ???itemlist.??? |
| Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation | Fountzilas, G.; Kourea, H. P.; Bobos, M.; Televantou, D.; Kotoula, V.; Papadimitriou, C.; Papazisis, K. T.; Timotheadou, E.; Efstratiou, I.; Koutras, A.; Pentheroudakis, G.; Christodoulou, C.; Aravantinos, G.; Miliaras, D.; Petraki, K.; Papandreou, C. N.; Papakostas, P.; Bafaloukos, D.; Repana, D.; Razis, E.; Pectasides, D.; Dimopoulos, A. M. | 24-Nov-2015 | - |
| Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group | Fountzilas, G.; Kalofonos, H. P.; Dafni, U.; Papadimitriou, C.; Bafaloukos, D.; Papakostas, P.; Kalogera-Fountzila, A.; Gogas, H.; Aravantinos, G.; Moulopoulos, L. A.; Economopoulos, T.; Pectasides, D.; Maniadakis, N.; Siafaka, V.; Briasoulis, E.; Christodoulou, C.; Tsavdaridis, D.; Makrantonakis, P.; Razis, E.; Kosmidis, P.; Skarlos, D.; Dimopoulos, M. A. | 24-Nov-2015 | - |
| Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group | Fountzilas, G.; Papakostas, P.; Dafni, U.; Makatsoris, T.; Karina, M.; Kalogera-Fountzila, A.; Maniadakis, N.; Aravantinos, G.; Syrigos, K.; Bamias, A.; Christodoulou, C.; Economopoulos, T.; Kalofonos, H.; Nikolaou, A.; Angouridakis, N.; Stathopoulos, G.; Bafaloukos, D.; Pavlidis, N.; Daniilidis, J. | 24-Nov-2015 | - |
| Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study | Aravantinos, G.; Fountzilas, G.; Kosmidis, P.; Dimopoulos, M. A.; Stathopoulos, G. P.; Pavlidis, N.; Bafaloukos, D.; Papadimitriou, C.; Karpathios, S.; Georgoulias, V.; Papakostas, P.; Kalofonos, H. P.; Grimani, E.; Skarlos, D. V. | 24-Nov-2015 | - |
| Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study | Skarlos, D. V.; Aravantinos, G.; Kosmidis, P.; Athanassiadis, A.; Stathopoulos, G. P.; Pavlidis, N.; Bafaloukos, D.; Karphathios, S.; Papakostas, P.; Bamia, C.; Fountzilas, G. | 24-Nov-2015 | - |
| Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors | Pentheroudakis, G.; Fountzilas, G.; Kalofonos, H. P.; Golfinopoulos, V.; Aravantinos, G.; Bafaloukos, D.; Papakostas, P.; Pectasides, D.; Christodoulou, C.; Syrigos, K.; Economopoulos, T.; Pavlidis, N. | 24-Nov-2015 | - |
| Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study | Briasoulis, E.; Golfinopoulos, V.; Karina, M.; Papakostas, P.; Pavlidis, N.; Fountzilas, G. | 24-Nov-2015 | - |
| Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group | Fountzilas, G.; Skarlos, D.; Dafni, U.; Gogas, H.; Briasoulis, E.; Pectasides, D.; Papadimitriou, C.; Markopoulos, C.; Polychronis, A.; Kalofonos, H. P.; Siafaka, V.; Kosmidis, P.; Timotheadou, E.; Tsavdaridis, D.; Bafaloukos, D.; Papakostas, P.; Razis, E.; Makrantonakis, P.; Aravantinos, G.; Christodoulou, C.; Dimopoulos, A. M. | 24-Nov-2015 | - |
| Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00 | Fountzilas, G.; Dafni, U.; Gogas, H.; Linardou, H.; Kalofonos, H. P.; Briasoulis, E.; Pectasides, D.; Samantas, E.; Bafaloukos, D.; Stathopoulos, G. P.; Karina, M.; Papadimitriou, C.; Skarlos, D.; Pisanidis, N.; Papakostas, P.; Markopoulos, C.; Tzorakoeleftherakis, E.; Dimitrakakis, K.; Makrantonakis, P.; Xiros, N.; Polichronis, A.; Varthalitis, I.; Karanikiotis, C.; Dimopoulos, A. M. | 24-Nov-2015 | - |
| Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial | Gogas, H.; Dafni, U.; Karina, M.; Papadimitriou, C.; Batistatou, A.; Bobos, M.; Kalofonos, H. P.; Eleftheraki, A. G.; Timotheadou, E.; Bafaloukos, D.; Christodoulou, C.; Markopoulos, C.; Briasoulis, E.; Papakostas, P.; Samantas, E.; Kosmidis, P.; Stathopoulos, G. P.; Karanikiotis, C.; Pectasides, D.; Dimopoulos, M. A.; Fountzilas, G. | 24-Nov-2015 | - |
| Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study | Razis, E.; Briasoulis, E.; Vrettou, E.; Skarlos, D. V.; Papamichael, D.; Kostopoulos, I.; Samantas, E.; Xanthakis, I.; Bobos, M.; Galanidi, E.; Bai, M.; Gikonti, I.; Koukouma, A.; Kafiri, G.; Papakostas, P.; Kalogeras, K. T.; Kosmidis, P.; Fountzilas, G. | 24-Nov-2015 | - |
| Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study | Fostira, F.; Tsitlaidou, M.; Papadimitriou, C.; Pertesi, M.; Timotheadou, E.; Stavropoulou, A. V.; Glentis, S.; Bournakis, E.; Bobos, M.; Pectasides, D.; Papakostas, P.; Pentheroudakis, G.; Gogas, H.; Skarlos, P.; Samantas, E.; Bafaloukos, D.; Kosmidis, P. A.; Koutras, A.; Yannoukakos, D.; Konstantopoulou, I.; Fountzilas, G. | 24-Nov-2015 | - |
| A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study | Kalofonos, H. P.; Bamias, A.; Koutras, A.; Papakostas, P.; Basdanis, G.; Samantas, E.; Karina, M.; Misailidou, D.; Pisanidis, N.; Pentheroudakis, G.; Economopoulos, T.; Papadimitriou, C.; Skarlos, D. V.; Pectasides, D.; Stavropoulos, M.; Bafaloukos, D.; Kardamakis, D.; Karanikiotis, C.; Vourli, G.; Fountzilas, G. | 24-Nov-2015 | - |
| A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study | Bafaloukos, D.; Linardou, H.; Aravantinos, G.; Papadimitriou, C.; Bamias, A.; Fountzilas, G.; Kalofonos, H. P.; Kosmidis, P.; Timotheadou, E.; Makatsoris, T.; Samantas, E.; Briasoulis, E.; Christodoulou, C.; Papakostas, P.; Pectasides, D.; Dimopoulos, A. M. | 24-Nov-2015 | - |
| A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study | Fountzilas, G.; Dafni, U.; Dimopoulos, M. A.; Koutras, A.; Skarlos, D.; Papakostas, P.; Gogas, H.; Bafaloukos, D.; Kalogera-Fountzila, A.; Samantas, E.; Briasoulis, E.; Pectasides, D.; Maniadakis, N.; Matsiakou, F.; Aravantinos, G.; Papadimitriou, C.; Karina, M.; Christodoulou, C.; Kosmidis, P.; Kalofonos, H. P. | 24-Nov-2015 | - |
| A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer | Bamias, A.; Karina, M.; Papakostas, P.; Kostopoulos, I.; Bobos, M.; Vourli, G.; Samantas, E.; Christodoulou, Ch; Pentheroudakis, G.; Pectasides, D.; Dimopoulos, M. A.; Fountzilas, G. | 24-Nov-2015 | - |
| A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study | Papadimitriou, C. A.; Papakostas, P.; Karina, M.; Malettou, L.; Dimopoulos, M. A.; Pentheroudakis, G.; Samantas, E.; Bamias, A.; Miliaras, D.; Basdanis, G.; Xiros, N.; Klouvas, G.; Bafaloukos, D.; Kafiri, G.; Papaspirou, I.; Pectasides, D.; Karanikiotis, C.; Economopoulos, T.; Efstratiou, I.; Korantzis, I.; Pisanidis, N.; Makatsoris, T.; Matsiakou, F.; Aravantinos, G.; Kalofonos, H. P.; Fountzilas, G. | 24-Nov-2015 | - |
| Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival | Kostadima, L.; Pentheroudakis, G.; Fountzilas, G.; Dimopoulos, M.; Pectasides, D.; Gogas, H.; Stropp, U.; Christodoulou, C.; Samantas, E.; Wirtz, R.; Hennig, G.; Bafaloukos, D.; Arapantoni, P.; Kalofonos, H.; Papakostas, P.; Economopoulos, T.; Bamias, A.; Pavlidis, N. | 24-Nov-2015 | - |
| Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy | Kostopoulos, I.; Karavasilis, V.; Karina, M.; Bobos, M.; Xiros, N.; Pentheroudakis, G.; Kafiri, G.; Papakostas, P.; Vrettou, E.; Fountzilas, G. | 24-Nov-2015 | - |
